-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026

PUBT·09/10/2026 11:02:06
Listen to the news
BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026
  • BioLineRx set two GLIX1 abstracts for EANO 2026, including preclinical efficacy data in glioblastoma models.
  • Results will be presented September 25, 2026; the company framed the studies as showing strong anti-tumor activity and a survival benefit.
  • A separate e-poster outlines an actively enrolling first-in-human Phase 1/2a trial in recurrent or progressive high-grade glioma.
  • The program targets a high-need brain cancer market; upcoming conference readouts could shape investor expectations for early clinical traction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004479), on September 10, 2026, and is solely responsible for the information contained therein.